Decibel Therapeutics Inc
NASDAQ:DBTX
Intrinsic Value
Decibel Therapeutics, Inc. discovers and develops medicines to protect, repair, and restore hearing. [ Read More ]
The intrinsic value of one DBTX stock under the Base Case scenario is 1.76 USD. Compared to the current market price of 4.91 USD, Decibel Therapeutics Inc is Overvalued by 64%.
Valuation Backtest
Decibel Therapeutics Inc
Run backtest to discover the historical profit from buying and selling DBTX stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Decibel Therapeutics Inc
Current Assets | 80.4m |
Cash & Short-Term Investments | 78.3m |
Other Current Assets | 2.1m |
Non-Current Assets | 13.9m |
PP&E | 13m |
Other Non-Current Assets | 934k |
Current Liabilities | 26.6m |
Accounts Payable | 617k |
Accrued Liabilities | 13.9m |
Other Current Liabilities | 12.1m |
Non-Current Liabilities | 14.5m |
Long-Term Debt | 46k |
Other Non-Current Liabilities | 14.5m |
Earnings Waterfall
Decibel Therapeutics Inc
Revenue
|
0
USD
|
Operating Expenses
|
-66m
USD
|
Operating Income
|
-66m
USD
|
Other Expenses
|
2.6m
USD
|
Net Income
|
-63.4m
USD
|
Free Cash Flow Analysis
Decibel Therapeutics Inc
What is Free Cash Flow?
DBTX Profitability Score
Profitability Due Diligence
Decibel Therapeutics Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
Score
Decibel Therapeutics Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
DBTX Solvency Score
Solvency Due Diligence
Decibel Therapeutics Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Score
Decibel Therapeutics Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
DBTX Price Targets Summary
Decibel Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for DBTX is 10 USD .
Ownership
DBTX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
DBTX Price
Decibel Therapeutics Inc
Average Annual Return | -72.1% |
Standard Deviation of Annual Returns |
N/A
|
Max Drawdown | -91% |
Market Capitalization | 123.4m USD |
Shares Outstanding | 25 126 900 |
Percentage of Shares Shorted | 0.65% |
DBTX News
Last Important Events
Decibel Therapeutics Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Decibel Therapeutics Inc
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Decibel Therapeutics, Inc. discovers and develops medicines to protect, repair, and restore hearing. The company is headquartered in Boston, Massachusetts and currently employs 62 full-time employees. The company went IPO on 2021-02-12. The firm is focused on discovering and developing transformative treatments for hearing and balance disorder. The company is focused on restoring and improving hearing and balance through the restoration and regeneration of functional hair cells and non-sensory support cells within the inner ear. The firm has built a platform that integrates single-cell genomics and bioinformatics analyses, precision gene therapy technologies and its proficiency in inner ear biology. The Company’s pipeline product includes its gene therapy program, namely DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin (OTOF) deficiency. In addition to its gene therapy product candidate and programs, it is also developing a clinical-stage product candidate, DB-020, for the prevention of cisplatin-induced hearing loss. Its products pipeline also includes AAV.103, AAV.104, DB-ATO and AAV.201.
Contact
IPO
Employees
Officers
The intrinsic value of one DBTX stock under the Base Case scenario is 1.76 USD.
Compared to the current market price of 4.91 USD, Decibel Therapeutics Inc is Overvalued by 64%.